Prospective Study on the Use of Transdermal Analgesic Buprenorphine Patches for Chronic Pain in the UK
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The primary objective of the study is the descriptive analysis of incidence & severity of side effects & reasons for discontinuation of the treatment of chronic pain with transdermal analgesic Buprenorphine patches.
Condition or disease
750 patients that are treated with transdermal Buprenorphine patches for chronic pain will be included in the study. About 20% of patients are aimed to be patch-naive, ie have received their first prescription of transdermal analgesic patches within 1 month before inclusion in this observational study. Furthermore the study should not include more than 25% of cancer patients that are treated for chronic pain in order to ensure an appropriate mix of patient population.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients experiencing pain. They may be from primary or secondary care.
Patient age > 18
Patient is treated with transdermal Buprenorphine
The patient is able to answer the patient's survey & has an estimated overall survival of minimum 6 months
The patient gives his/her informed, written consent to participate in the study
Patient Age < 18
Patient has less than 6 months survival expectancy
Patient is unable to answer the patient survey for whatever reason in any feasible form